Geron Co. (GERN) Receives Average Rating of “Hold” from Brokerages

Geron Co. (NASDAQ:GERN) has received a consensus rating of “Hold” from the six research firms that are presently covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $3.75.

Several equities research analysts have issued reports on GERN shares. Zacks Investment Research lowered shares of Geron from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd. BidaskClub upgraded shares of Geron from a “strong sell” rating to a “sell” rating in a research report on Thursday, January 11th. Stifel Nicolaus reiterated a “hold” rating and set a $2.50 target price on shares of Geron in a research report on Friday, November 3rd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Geron in a research report on Friday, November 3rd.

Shares of Geron (NASDAQ GERN) opened at $2.25 on Friday. Geron has a 1 year low of $1.74 and a 1 year high of $3.15. The stock has a market cap of $358.27, a P/E ratio of -12.50 and a beta of 2.81.

Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Geron by 4.1% in the 2nd quarter. Vanguard Group Inc. now owns 7,406,968 shares of the biopharmaceutical company’s stock worth $20,518,000 after acquiring an additional 294,785 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Geron by 783.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 363,990 shares of the biopharmaceutical company’s stock worth $794,000 after acquiring an additional 322,810 shares during the last quarter. State Street Corp lifted its holdings in shares of Geron by 9.8% in the 2nd quarter. State Street Corp now owns 5,127,578 shares of the biopharmaceutical company’s stock worth $14,205,000 after acquiring an additional 459,700 shares during the last quarter. Raymond James Financial Services Advisors Inc. lifted its holdings in shares of Geron by 42.0% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 82,426 shares of the biopharmaceutical company’s stock worth $180,000 after acquiring an additional 24,370 shares during the last quarter. Finally, Creative Planning lifted its holdings in shares of Geron by 69.8% in the 4th quarter. Creative Planning now owns 308,523 shares of the biopharmaceutical company’s stock worth $555,000 after acquiring an additional 126,810 shares during the last quarter. Hedge funds and other institutional investors own 39.32% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.com-unik.info/2018/02/10/geron-co-gern-receives-average-rating-of-hold-from-brokerages.html.

About Geron

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit